Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Brooklyn Immunotherapeutics Inc (NQ: BTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 14, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Brooklyn Immunotherapeutics Inc Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 August 16, 2021 LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be... From Stock News Now Via AccessWire Topics Cannabis Exposures Cannabis 50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 July 08, 2021 RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... From Access to Giving Via AccessWire Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call May 26, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing May 24, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. May 21, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET May 18, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research May 11, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics May 07, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders April 29, 2021 From Brooklyn ImmunoTherapeutics LLC Via Business Wire Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics April 26, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Brooklyn ImmunoTherapeutics Reports Inducement Grants April 19, 2021 From Brooklyn ImmunoTherapeutics LLC Via Business Wire Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders April 15, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc. April 15, 2021 From Brooklyn ImmunoTherapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.